Description: MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.Together with its partners in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline of drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer�s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow.Over 70 therapeutic antibody programs based on the company�s technologies are currently in development, of which 20 are in clinical trials. The company�s most advanced proprietary program is MOR103, a first-in-class antibody against GM-CSF for the treatment of rheumatoid arthritis and multiple sclerosis. MOR103 is part of MorphoSys's collaboration with GlaxoSmithKline. Other proprietary clinical programs include MOR208 and MOR202, both for the treatment of cancer.MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.
Home Page: www.morphosys.com
Semmelweisstrasse 7
Planegg,
82152
Germany
Phone:
49 89 899 27 0
Officers
| Name | Title |
|---|---|
| Ms. Charlotte Lohmann | Chief Legal and Human Resources Officer & Member of Management Board |
| Mr. Arkadius Pichota M.B.A., Ph.D. | Chief Executive Officer |
| Mr. Lukas Gilgen | Chief Financial Officer |
| Mr. Klaus De Wall | Head of Accounting & Tax |
| Dr. Margit Urban | Head of Discovery Alliances & Technologies |
| Dr. Julia Neugebauer Ph.D. | Head of Investor Relations |
| Dr. Barbara Krebs-Pohl Ph.D. | Chief Business Officer |
| Dr. Günter Wellnhofer | Head of Technical Operations |
| Dr. Harald Watzka | Head of Alliance Management |
| Ms. Yen Ching Chua | Head of Clinical Operations |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 322.5806 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 51.5444 |
| Price-to-Sales TTM: | 12.3774 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 524 |